| 摘要 |
Radioimmunotoxins consisting of a monoclonal antibody covalently coupled to a toxin and a radionuclide. The compositions retain high binding specificity and cytotoxic activity and are useful in treating cancer and in bone marrow transplantation. The antibody component determines the selectivity. The toxin component kills the targeted cells. The radionuclide component also kills, but by a different mechanism, thus ensuring the eradication of all tumor cells. The radionuclide also allows the radioimmunotoxin to be tracked in vivo which enables the determination of its distribution throughout the body. Also, the pharmacokinetics of injected radioimmunotoxin can be determined allowing for more exact dose quantitation and administration.
|
